In the phase 3 PROOF-HD trial, pridopidine shows consistent motor function improvements in Q-Motor measures, supporting Q-Motor as a predictive measure of long-term functional bene... by Michal Geva, Ralf Reilmann, Robin Schubert, Kelly Chen, Y Paul Goldberg, Michael R. Hayden

Get full text

The phase 3 PROOF-HD trial demonstrates persistent benefits of pridopidine on function, cognition, and motor function through the 6 month open label extension in Huntington disease... by Michal Geva, Ralf Reilmann, Andrew Feigin, Anne Rosser, Sandra Kostyk, Kelly Chen, Yael Cohen, Y Paul Goldberg, Michael R. Hayden

Get full text

Life-Threatening Adverse Events Following Therapeutic Opioid Administration in Adults: Is Pharmacogenetic Analysis Useful? by Parvaz Madadi, Johanna Sistonen, Gregory Silverman, Rebecca Gladdy, Colin J Ross, Bruce C Carleton, Jose C Carvalho, Michael R Hayden, Gideon Koren

Get full text

Pridopidine treatment benefits in definite, probable, and early (<18mo onset) subjects with ALS in the HEALEY ALS Platform Trial by Michal Geva, Y Paul Goldberg, Melanie L. Leitner, Kelly Chen, Wei Feng, Noga Gershoni Emek, James D. Berry, Sabrina Paganoni, Jeremy Shefner, Merit ECudkowicz, Michael R. Hayden

Get full text

Challenges and advances for huntingtin detection in cerebrospinal fluid: in support of relative quantification by Rachel J. Harding, Yuanyun Xie, Nicholas S. Caron, Hailey Findlay-Black, Caroline Lyu, Nalini Potluri, Renu Chandrasekaran, Michael R. Hayden, Blair R. Leavitt, Douglas R. Langbehn, Amber L. Southwell

Get full text

CAG-targeted brain-permeable therapy tested in biallelic humanized polyQ mouse models by Magdalena Surdyka, Żaneta Kalinowska-Pośka, Anna Niewiadomska-Cimicka, Ewelina Jesion, Agnieszka Fiszer, Elisabeth Singer-Mikosch, Lorraine Fievet, Lukasz Przybyl, Nicholas S. Caron, Michael R. Hayden, Huu Phuc Nguyen, Yvon Trottier, Maciej Figiel

Get full text